The Progeria Research Foundation (PRF) is a driving force worldwide in finding treatments and the cure for Progeria and its aging-related disorders, including heart disease. PRF has brought Progeria to the forefront of research efforts, engaging large, reputable institutions in Progeria research. This has resulted in major discoveries and over 200 peer-reviewed scientific publications. In addition, NIH has co-sponsored 11 scientific workshops with PRF, and Boston Children’s Hospital has partnered with PRF on 4 Progeria Clinical Drug Trials.
We invite qualified scientists with faculty appointments or the equivalent to submit applications for the 2021/2022 grant cycles
PRF’s research focus is highly translational. Topics must fall within the following research priorities:
- Projects that are likely to lead to clinical treatment trials within 5 years. This includes the discovery and/or testing of candidate treatment compounds in cell-based or animal models of HGPS. Only proposals that test compounds in a progerin-producing animal or cell model will normally be considered. Analyses in non progerin-producing models are acceptable, but only as a comparison to progerin-producing models and with strong justification.
- Development of gene- and cell-based therapies to treat Progeria
- Assessment of natural disease history of disease that may be important to developing outcome measures in treatment trials (preclinical or clinical)
Awards are typically for 1-2 years in the range of $75,000/year.
Please click here for instructions to submit a letter of intent, the grant application, deadlines and more detailed guidelines.